Siemens Issues Statement on USPSTF Draft Recommendation

Jul 29, 2013

As a leading manufacturer of CT technology, Siemens Healthcare supports the final evidence report and draft recommendation statement ( issued by the U.S. Preventive Services Task Force (USPSTF) regarding CT screening for lung cancer.


“The USPSTF recommendation reinforces the clinical and economic value of accurate and timely diagnosis,” said Gregory Sorensen, MD, CEO of Siemens Healthcare North America. “Lung cancer is one of the most prevalent and deadly cancers, and accurate and timely diagnosis is essential to helping clinicians and patients fight this devastating disease.”


Siemens will continue to support imaging research and better serve patients around the world by providing clinicians access to efficient and effective CT solutions. Siemens has long believed that its innovative imaging technology makes a positive impact on fighting disease and improving lives.1


Contact for journalists:

Jeff Bell
Siemens Healthcare Media Relations
Phone: +1 610-448-1477; E-mail:

Follow us on Twitter at:



Launched in November 2011, Agenda 2013 is the initiative of the Siemens Healthcare Sector to further strengthen its innovative power and competitiveness. Specific measures, which will be implemented by the end of 2013, have been defined in four fields of action: innovation, competitiveness, regional footprint, and people development.


The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of around 1.8 billion euros. For further information please visit:

1Siemens CT systems are indicated for low-dose lung imaging and not lung cancer screening.